Drug class review on HMG-CoA reductase inhibitors (statins) final report
In the United States, coronary heart disease (CHD) and cardiovascular disease (CVD) account for nearly 40% of all deaths each year. High levels of cholesterol, or hypercholesterolemia, are an important risk factor for CHD. The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, also...
| Main Author: | |
|---|---|
| Corporate Author: | |
| Other Authors: | , |
| Format: | eBook |
| Language: | English |
| Published: |
Portland, Or.
Oregon Health & Science University, Evidence-Based Practice Center
2006, c2006
|
| Series: | Drug class reviews
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references